Fransisco Garcia Pons

Title: Fransisco Garcia Pons: Innovator in Anticancer Therapy

Introduction

Fransisco Garcia Pons is a notable inventor based in Maurepas, France. He has made significant contributions to the field of anticancer therapy, particularly through his innovative work on polynucleotides and immunogenic peptides. With a total of 4 patents, his research has the potential to impact cancer treatment and prevention.

Latest Patents

One of his latest patents focuses on "Polynucleotides encoding MHC class I-restricted hTERT epitopes, analogues thereof or polyepitopes." This invention is crucial in the field of anticancer therapy, as it identifies immunogenic peptides derived from the human telomerase reverse transcriptase (hTERT). The patent details polynucleotides that encode hTERT epitopes restricted to MHC class I molecules, along with their analogues and polyepitopes. Additionally, it includes vectors and cells that comprise these polynucleotides. The invention also encompasses compositions that include hTERT polypeptides, corresponding polynucleotides, vectors, and cells, aimed at the treatment and prevention of cancer.

Career Highlights

Fransisco Garcia Pons has worked with prestigious organizations such as Institut Pasteur and the National Institute of Health and Medical Research. His experience in these institutions has allowed him to collaborate with leading experts in the field, enhancing his research and innovation capabilities.

Collaborations

Some of his notable coworkers include Pierre Langlade-Demoyen and Olivier Adotevi. Their collaborative efforts have contributed to advancing research in anticancer therapies.

Conclusion

Fransisco Garcia Pons is a prominent figure in the realm of anticancer research, with a focus on innovative solutions that leverage polynucleotides and immunogenic peptides. His work continues to pave the way for advancements in cancer treatment and prevention.